Web 3.0数字经济体系以区块链平台为基础设施,围绕加密货币、NFT、数字藏品等数字资产和去中心化金融(DeFi)、游戏金融(GameFi)等去中心化应用(DApp)开展各项社会经济活动.在公有链和开放联盟链下,作为DApp内核的智能合约可以由任何个...Web 3.0数字经济体系以区块链平台为基础设施,围绕加密货币、NFT、数字藏品等数字资产和去中心化金融(DeFi)、游戏金融(GameFi)等去中心化应用(DApp)开展各项社会经济活动.在公有链和开放联盟链下,作为DApp内核的智能合约可以由任何个人或组织予以部署,并对全体用户可见及可调用.这种开放性给经济发展带来了新的机遇,同时也蕴含了许多金融风险.以智能合约为中心分析了Web 3.0数字经济潜在的风险,并从智能合约的编码、功能、应用3个层面总结了风险感知技术的研究现状.首先介绍了智能合约漏洞检测技术的研究挑战、安全漏洞类型和4类漏洞检测方法;其次分析了常见的智能合约骗局类型,并根据训练数据的不同分类总结了现有的智能合约骗局识别技术;接着介绍了基于区块链交易记录对4种非法交易行为进行检测的技术现状;最后结合对现有工作局限性的分析,展望了未来的研究方向.展开更多
目的探讨3.0 T磁共振成像(MRI)联合多层螺旋电子计算机断层扫描(MSCT)对肛瘘临床分型的诊断价值。方法回顾性分析2020年1月至2022年5月在石家庄市中医院经手术证实的126例肛瘘病人临床资料,术前均行3.0 T MRI和MSCT检查。根据Parks分类...目的探讨3.0 T磁共振成像(MRI)联合多层螺旋电子计算机断层扫描(MSCT)对肛瘘临床分型的诊断价值。方法回顾性分析2020年1月至2022年5月在石家庄市中医院经手术证实的126例肛瘘病人临床资料,术前均行3.0 T MRI和MSCT检查。根据Parks分类法对比3.0 T MRI和MSCT对肛瘘病人检查的准确率,分析两项联合对肛瘘临床分型的诊断价值。结果3.0 T MRI联合MSCT诊断肛瘘外口的准确率(99.03%)高于MSCT单独诊断(90.29%),联合诊断主瘘管的准确率(100.00%)高于3.0 T MRI、MSCT各自单独诊断(93.65%、91.27%)(P<0.01),联合诊断肛瘘内口、瘘管分支、脓肿与各自单独诊断比较均差异无统计学意义(P>0.05);3.0 T MRI联合MSCT诊断括约肌间型、经括约肌型、括约肌上型、括约肌外型与手术结果的符合率分别为98.48%、100.00%、100.00%、100.00%。结论3.0 T MRI联合MSCT对肛瘘临床分型有良好的诊断价值。展开更多
BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is a highly fatal disease with limited effective treatment especially after first-line chemotherapy.The human epidermal growth factor receptor 2(HER-2)immunohistochemis...BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is a highly fatal disease with limited effective treatment especially after first-line chemotherapy.The human epidermal growth factor receptor 2(HER-2)immunohistochemistry(IHC)positive is associated with more aggressive clinical behavior and shorter overall survival in PDAC.CASE SUMMARY We present a case of multiple metastatic PDAC with IHC mismatch repair proficient but HER-2 IHC weakly positive at diagnosis that didn’t have tumor regression after first-line nab-paclitaxel plus gemcitabine and PD-1 inhibitor treatment.A novel combination therapy PRaG 3.0 of RC48(HER2-antibody-drug conjugate),radio-therapy,PD-1 inhibitor,granulocyte-macrophage colony-stimulating factor and interleukin-2 was then applied as second-line therapy and the patient had confirmed good partial response with progress-free-survival of 6.5 months and overall survival of 14.2 month.She had not developed any grade 2 or above treatment-related adverse events at any point.Percentage of peripheral CD8^(+) Temra and CD4^(+) Temra were increased during first two activation cycles of PRaG 3.0 treatment containing radiotherapy but deceased to the baseline during the maintenance cycles containing no radiotherapy.CONCLUSION PRaG 3.0 might be a novel strategy for HER2-positive metastatic PDAC patients who failed from previous first-line approach and even PD-1 immunotherapy but needs more data in prospective trials.展开更多
文摘目的探讨3.0 T磁共振成像(MRI)联合多层螺旋电子计算机断层扫描(MSCT)对肛瘘临床分型的诊断价值。方法回顾性分析2020年1月至2022年5月在石家庄市中医院经手术证实的126例肛瘘病人临床资料,术前均行3.0 T MRI和MSCT检查。根据Parks分类法对比3.0 T MRI和MSCT对肛瘘病人检查的准确率,分析两项联合对肛瘘临床分型的诊断价值。结果3.0 T MRI联合MSCT诊断肛瘘外口的准确率(99.03%)高于MSCT单独诊断(90.29%),联合诊断主瘘管的准确率(100.00%)高于3.0 T MRI、MSCT各自单独诊断(93.65%、91.27%)(P<0.01),联合诊断肛瘘内口、瘘管分支、脓肿与各自单独诊断比较均差异无统计学意义(P>0.05);3.0 T MRI联合MSCT诊断括约肌间型、经括约肌型、括约肌上型、括约肌外型与手术结果的符合率分别为98.48%、100.00%、100.00%、100.00%。结论3.0 T MRI联合MSCT对肛瘘临床分型有良好的诊断价值。
基金the Suzhou Medical Center,No.Szlcyxzx202103the National Natural Science Foundation of China,No.82171828+9 种基金the Key R&D Plan of Jiangsu Province(Social Development),No.BE2021652the Subject Construction Support Project of The Second Affiliated Hospital of Soochow University,No.XKTJHRC20210011Wu Jieping Medical Foundation,No.320.6750.2021-01-12the Special Project of“Technological Innovation”Project of CNNC Medical Industry Co.Ltd,No.ZHYLTD2021001Suzhou Science and Education Health Project,No.KJXW2021018Foundation of Chinese Society of Clinical Oncology,No.Y-pierrefabre202102-0113Beijing Bethune Charitable Foundation,No.STLKY0016Research Projects of China Baoyuan Investment Co.,No.270004Suzhou Gusu Health Talent Program,No.GSWS2022028Open Project of State Key Laboratory of Radiation Medicine and Protection of Soochow University,No.GZN1202302.
文摘BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is a highly fatal disease with limited effective treatment especially after first-line chemotherapy.The human epidermal growth factor receptor 2(HER-2)immunohistochemistry(IHC)positive is associated with more aggressive clinical behavior and shorter overall survival in PDAC.CASE SUMMARY We present a case of multiple metastatic PDAC with IHC mismatch repair proficient but HER-2 IHC weakly positive at diagnosis that didn’t have tumor regression after first-line nab-paclitaxel plus gemcitabine and PD-1 inhibitor treatment.A novel combination therapy PRaG 3.0 of RC48(HER2-antibody-drug conjugate),radio-therapy,PD-1 inhibitor,granulocyte-macrophage colony-stimulating factor and interleukin-2 was then applied as second-line therapy and the patient had confirmed good partial response with progress-free-survival of 6.5 months and overall survival of 14.2 month.She had not developed any grade 2 or above treatment-related adverse events at any point.Percentage of peripheral CD8^(+) Temra and CD4^(+) Temra were increased during first two activation cycles of PRaG 3.0 treatment containing radiotherapy but deceased to the baseline during the maintenance cycles containing no radiotherapy.CONCLUSION PRaG 3.0 might be a novel strategy for HER2-positive metastatic PDAC patients who failed from previous first-line approach and even PD-1 immunotherapy but needs more data in prospective trials.
